About: Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.81 (-1.63%)
GRCE NASDAQ Grace Therapeutics, Inc.
Grace Therapeutics, Inc. share price
Atividade de preço de GRCE
Último preço
$ 1,810
Variação (24h)
-0,03 USD (1,63%)
Volume
64.53K
Volume (média 4 sem.)
-
Abertura
$ 1,85
Variação do dia
$ 1,78 - $ 1,96
Fechamento anterior
$ 1,84
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
GRCE price performance
Atrasado
04 Nov, 9:00 pm GMT+0
GRCE details
quote.marketSignals